Omeros
About OmerosPipelineInvestorsNews


Investor Relations Home

Corporate Profile

Here you will find financial reports and shareholder information about Omeros Corporation, including recent news, current and historical share price, and electronic copies of our SEC filings.

 
Stock Quote
OMER (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$13.39
Change (%) Stock is Down 0.96 (6.69%)
Volume791,687
Data as of 12/13/18 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent Press ReleasesMore >>
DateTitle  
12/11/18Omeros Announces Research Collaboration with University of Cambridge
Newly Established Center Will Focus on Complement and Inflammation SEATTLE--(BUSINESS WIRE)--Dec. 11, 2018-- Omeros Corporation (Nasdaq: OMER) today announced that it has entered into a research collaboration with the University of Cambridge, establishing the Omeros Center at Cambridge for Complement and Inflammation Research (OC3IR). The OC3IR currently is focusing on research related to OMS721, Omeros’ lead human monoclonal antibody targetin... 
 Printer Friendly Version
12/06/18Omeros Announces Clinical Strategy to Accelerate Pediatric Development of OMS721 for the Treatment of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA)
– EMA Confirmed OMS721 Eligibility for European Centralized Marketing Authorization Application Review – SEATTLE--(BUSINESS WIRE)--Dec. 6, 2018-- Omeros Corporation (Nasdaq: OMER) today announced that it has submitted a pediatric investigational plan (PIP) for the use of OMS721 for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) to the European Medicines Association (EMA). A pediatric study ... 
 Printer Friendly Version
12/03/18Omeros Announces Additions to Senior Management Team
-- Hires Commercial and CMC Heads from Celgene -- SEATTLE--(BUSINESS WIRE)--Dec. 3, 2018-- Omeros Corporation (Nasdaq: OMER) today announced that it hired two new senior management team members – Daniel Kirby as vice president and head of commercial and Justin McCue, Ph.D. as vice president of chemistry, manufacturing and controls (CMC). Their respective responsibilities cover all of Omeros’ programs, with the current primary areas of focus fo... 
 Printer Friendly Version
11/09/18Omeros Announces Pricing of $210 Million Offering of Convertible Senior Notes Due 2023
-- Initial Purchasers Have Option to Purchase $40 Million of Additional Notes -- SEATTLE--(BUSINESS WIRE)--Nov. 9, 2018-- Omeros Corporation (Nasdaq: OMER) (“Omeros”) today announced the pricing of an offering of $210 million aggregate principal amount of its 6.25% Convertible Senior Notes due 2023 (the “Notes”) in a private offering (the “Offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933 (the ... 
 Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Featured Report
Download Documentation Corporate Presentation
Download Documentation 2017 Annual Report
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Omeros Corporation posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.